Ordesa saw turnover grow to €112.4 millions, up 4.7%, in 2014
Laboratorios Ordesa today announced its results for the 2014 year, which reveal a growing trend mainly due to increased sales, cutting structural costs, implementing more efficient sales policies and consolidating foreign markets the company had opened in previous years. Since 2007, the Ordesa Group has a R&D&i center at Barcelona Science Park, from where the company actively participates in clinical studies and national and international research projects in the areas of immunology and cognitive development. The elaboration of hydrolyzed cereals, liquid milk, or the launching of the first porridge with bifidus effect, and supplemented infant formulas are some of the results from these projects.
Ordesa saw turnover grow to €112.4 millions, up 4.7%, in 2014. By 2020, the company aims to hit €200 millions in turnover, and is focusing its efforts on international growth to do so. In 2014, the company’s sales abroad grew 16%, putting international business at 45% of total turnover, after entering China and Turkey.
As a result, Laboratorios Ordesa has launched a plan to grow in new markets and double current sales over the coming 5 years. The company is currently present in 15 countries, mainly in the Middle East, where its main foreign market is Saudi Arabia, and Latin America. It is focusing its strategy on continued growth in the Middle East, moving into northern Africa and expanding its presence in Asia.
In addition to international expansion, Laboratorios Ordesa expects 8.9% growth in 2015 through the consolidation of new product lines and its commitment to R&D&i. The company is currently working on an average of 15 new projects per year and collaborates with a network of more than 200 researchers around Spain on a regular basis.